SCHEMBL3274196

SCHEMBL3274196

Nc1ccc2nc3c(-c4cccoc4=O)cc(=O)cc-3oc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.39
NPC1 O15118 3/20 0.37
MEN1 O00255 3/20 0.37
RAB9A P51151 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
ALOX5 P09917 1/20 0.36
EPHX2 P34913 1/20 0.36
ADORA1 P30542 2/20 0.35
APP P05067 2/20 0.34
POLB P06746 2/20 0.33
PIK3R1 P27986 2/20 0.32
PIK3CA P42336 2/20 0.32
ALPL P05186 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666115 0.69 RAB9A (0.46) ADORA2ANPC1MEN1RAB9AKMT2A
SCHEMBL3275224 0.69 KMT2A (0.62) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL12984911 0.68 APP (0.57) MEN1KMT2AKDM4EHPGDAPP
SCHEMBL1635798 0.67 SRC (0.44) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL1635563 0.67 APP (0.68) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL1635260 0.67 RAB9A (0.44) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL826022 0.64 KMT2A (0.45) ADORA2ANPC1MEN1RAB9AKMT2A
SCHEMBL28236480 0.63 RAB9A (0.67) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL13338326 0.63 LCK (0.52) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL6235497 0.62 PIK3R1 (0.66) ADORA2AMEN1RAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7695930-B2 Method for the detection, identification and/or quantification of microoganisms with peptidase activity using phenoxazinone derivatives as enzyme substrates BIOMERIEUX (FR) 2010-04-13 US disclosed
US-20080286820-A1 Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2008-11-20 US disclosed
US-7420054-B2 Phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2008-09-02 US disclosed
EP-1625117-B1 NOVEL PHENOXAZINONE DERIVATIVES AS ENZYME SUBSTRATES AND USE THEREOF AS INDICTOR IN THE DETECTION OF MICROORGANISMS WITH PEPTIDASE ACTIVITY BIOMERIEUX SA (FR) 2008-01-09 EP disclosed
US-20060121551-A1 Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060121551-A1 Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity PEPD, CTRL, PM20D2 ADORA2A 2986/4885NPC1 4472/4885MEN1 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.